Applicant, as named in the Orange Book
Exelixis
Exelixis Inc · Nasdaq: EXEL
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Cometriq on 10 Feb 2032. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Cometriq NDA 203756 · 2 strengths cabozantinib s-malate | 10 Feb 2032 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.